As of Wednesday close, Design Therapeutics Inc.’s (NASDAQ:DSGN) stock was up $0.01, moving up 0.43 percent to $2.32. The average number of shares traded per day over the past five days has been 2,259,520 shares. 3 times new highs have been achieved over the past 5 days, with a $0.24 gain in that time frame. In the last twenty days, the average volume was 2,075,935, while in the previous 50 days, it was 980,446.
Since last month, DSGN stock retreated -69.87%. Shares of the company fell to $1.94 on 08/22/23, the lowest level in the past month. A 52-week high of $25.03 was reached on 01/03/23 after having rallying from a 52-week low of $1.94. Since the beginning of this year, DSGN’s stock price has dropped by -77.39% or -$7.94, and marked a new high 1 time. However, the stock has declined by -90.73% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
DSGN stock investors should be aware that Design Therapeutics Inc. (DSGN) stock had its last reported insider trading activity 2 days ago on Aug 29. William Arsani, the Director of the company, purchased of 1,960,000 shares for $2.44 on Aug 29. It resulted in a $4,782,400 investment by the insider. Prasad Deepa added 12,000 shares at an average price of $2.31 on Aug 29. The insider now owns 23,806 shares following the transaction. On Aug 28, Director William Arsani bought 275,000 shares at $2.15 apiece. The transaction was valued at $591,250.
Financial Health
In the three months ended June 29, Design Therapeutics Inc.’s quick ratio stood at 25.20, while its current ratio was 25.20, showing that the company is able to pay off its debt. Based on annual data, DSGN earned $67.59 million in gross profit.
While analysts expected Design Therapeutics Inc. to report -$0.4 quarterly earnings, the actual figure was -$0.36 per share. The liabilities of Design Therapeutics Inc. were 14.84 million at the end of its most recent quarter ended June 29, and its total debt was $3.38 million. The value of shareholders’ equity is $55.99 million.
Technical Picture
This quick technical analysis looks at Design Therapeutics Inc.’s (DSGN) price momentum. With a historical volatility rate of 40.29%, the RSI 9-day stood at 21.21% on 30 August.
With respect to its five-day moving average, the current Design Therapeutics Inc. price is up by +11.54% percent or $0.24. At present, DSGN shares trade -70.06% below its 20-day simple moving average and -57.31% percent below its 100-day simple moving average. However, the stock is currently trading approximately -59.23% below its SMA50 and -85.19% below its SMA200.
Stochastic coefficient K was 5.72% and Stochastic coefficient D was 4.32%, while ATR was 0.40. Given the Stochastic reading of 6.45% for the 14-day period, the RSI (14) reading has been calculated as 22.94%. As of today, the MACD Oscillator reading stands at 0.14, while the 14-day reading stands at -0.63.
Analyst Ratings
Design Therapeutics Inc. downgraded its rating on Design Therapeutics Inc. (NASDAQ: DSGN) to a Neutral in a note to investors on August 15, 2023. The analysts firm previously had an Outperform rating on the stock.Design Therapeutics Inc. (DSGN) has been rated Hold by analysts. According to 0 brokerage firms, DSGN is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Design Therapeutics Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $6.50, the current consensus forecast for the stock is $6.00 – $42.00. Based on these forecasts, analysts predict Design Therapeutics Inc. (DSGN) will achieve an average price target of $15.25.
